University Hospital Galway, Newcastle Road, Galway, Ireland.
Med Phys. 2013 Nov;40(11):111715. doi: 10.1118/1.4824433.
This study investigates the impact of systematic multileaf collimator (MLC) positional errors on gamma analysis results used for quality assurance (QA) of Rapidarc treatments. In addition, this study evaluates the relationship of these gamma analysis results and clinical dose volume histogram metrics (DVH) for Rapidarc treatment plans.
Five prostate plans were modified by the introduction of systematic MLC errors. The MLC shifts to each individual active leaf introduced were 0.25, 0.5, 0.75, and 1 mm. All QA verification plans were delivered and estimated 3D patient dose or high density phantom dose were obtained based on the ArcCHECK measurement files. QA gamma analysis of 3%/3 mm and 2%/2 mm were implemented and relationships to dose differences in DVH metrics encountered due to MLC errors were determined. Tolerances of 3% and 5% for DVH metric were implemented to determine the sensitivity of gamma analysis to MLC errors. A calculation of sensitivity was determined from the number of incidences of false negative and false positive cases in gamma analysis results.
The sensitivity of global gamma analysis for criteria of 3%/3 mm was 0.78 and for 2%/2 mm was 0.82. A number of instances occurred for an acceptable VMAT QA gamma index which did not indicate a DVH metric dose error greater than 5%. The correlation between global gamma analysis using criteria 3%/3 mm and DVH metric dose error were all <0.8 indicating less than a strong correlation.
There is a greater sensitivity for detection of dosimetric errors occurring in a Rapidarc plan using gamma criteria of 2%/2 mm than 3%/3 mm. However, there is lack of consistently strong correlation between global gamma indexes and clinical DVH metrics for PTV and bladder and rectum for Rapidarc plans. It is recommended that the sole use of gamma index for Rapidarc QA plan evaluation could be insufficient and a methodology for evaluation of delivered dose to patient is required.
本研究旨在探讨系统多叶准直器(MLC)位置误差对 Rapidarc 治疗剂量验证的伽马分析结果的影响。此外,本研究还评估了这些伽马分析结果与 Rapidarc 治疗计划临床剂量体积直方图(DVH)指标之间的关系。
通过引入系统 MLC 误差,对 5 个前列腺计划进行了修改。每个活动叶片的 MLC 移位量分别为 0.25、0.5、0.75 和 1mm。所有 QA 验证计划均已交付,并根据 ArcCHECK 测量文件获得了 3D 患者剂量或高密度体模剂量。实施了 3%/3mm 和 2%/2mm 的 QA 伽马分析,并确定了由于 MLC 误差导致的 DVH 指标剂量差异的关系。实施了 3%和 5%的 DVH 指标容限,以确定伽马分析对 MLC 误差的敏感性。通过计算伽马分析结果中假阴性和假阳性病例的数量来确定灵敏度。
3%/3mm 标准的全局伽马分析灵敏度为 0.78,2%/2mm 标准的灵敏度为 0.82。对于符合 VMAT QA 伽马指数要求的情况,有许多实例并未表明 DVH 指标剂量误差大于 5%。使用 3%/3mm 标准的全局伽马分析与 PTV 和膀胱、直肠的 DVH 指标剂量误差之间的相关性均<0.8,表明相关性较弱。
使用 2%/2mm 的伽马标准检测 Rapidarc 计划中出现的剂量误差的灵敏度高于 3%/3mm。然而,对于 Rapidarc 计划的 PTV 和膀胱、直肠,全局伽马指数与临床 DVH 指标之间缺乏一致的强相关性。建议仅使用伽马指数对 Rapidarc QA 计划评估可能不够充分,需要一种评估患者实际接受剂量的方法。